NICE backs radionuclide therapy for some neuroendocrine tumours
A price cut has secured NHS funding for Advanced Accelerator Applications’ Lutathera as a treatment for some neuroendocrine tumours (NETs).
Read More
Tag: lutetium Lu 177 dotatate
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
